Clinical Trial Update: Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating fecal microbiota transplant in combination with tislelizumab for advanced or metastatic non-small cell lung cancer. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Se-Hoon Lee | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING